In vitro experiments in PAH-hPASMCs suggest that Orai1 overexpression and overactivation are independent of the signaling pathways targeted in PAH, indicating that Orai1 inhibition could be complementary to current therapies. Here, ORAI1 is linked to pulmonary arterial hypertension.